Credit: Unsplash / CC0 Public Domain

US pharmaceutical company Pfizer expects to apply for emergency approval for its COVID-19 vaccine in late November, about two weeks after the November 3rd US presidential election.

The company hopes to advance the vaccine further after safety data is available in the third week of November and immediately increase the company’s stake in the US by two percent.

“Let me be clear that assuming positive data, Pfizer will file an application for emergency approval soon after the US safety milestone is reached in the third week of November,” said Company Chairman and CEO Albert Bourla in an open letter.

Follow the latest news on the Coronavirus (COVID-19) outbreak

© 2020 AFP

Quote: Pfizer plans to apply for Covid-19 vaccine approval in November: Company (2020, October 16) posted October 16, 2020 from -covid-vaccine-november accessed. html

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.


Please enter your comment!
Please enter your name here